Camblin, A. J. (2018). Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationCamblin, A. J. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationCamblin, A. J. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.